| __timestamp | Eli Lilly and Company | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 165772000 |
| Thursday, January 1, 2015 | 6533000000 | 196614000 |
| Friday, January 1, 2016 | 6452000000 | 303251000 |
| Sunday, January 1, 2017 | 6588100000 | 366406000 |
| Monday, January 1, 2018 | 5975100000 | 434407000 |
| Tuesday, January 1, 2019 | 6213800000 | 468711000 |
| Wednesday, January 1, 2020 | 6121200000 | 516922000 |
| Friday, January 1, 2021 | 6431600000 | 739560000 |
| Saturday, January 1, 2022 | 6440400000 | 1002140000 |
| Sunday, January 1, 2023 | 6941200000 | 1161300000 |
| Monday, January 1, 2024 | 8593800000 | 1242157000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Eli Lilly and Company and Incyte Corporation have demonstrated contrasting approaches to SG&A efficiency.
Eli Lilly, a stalwart in the industry, has consistently maintained high SG&A expenses, averaging around $6.4 billion annually from 2014 to 2023. Despite fluctuations, their expenses peaked in 2023, reflecting a strategic investment in administrative capabilities. In contrast, Incyte Corporation, a smaller player, has shown a remarkable upward trend, with SG&A expenses growing by over 600% from 2014 to 2023. This growth underscores Incyte's aggressive expansion and market penetration strategies.
Understanding these trends provides valuable insights into how these companies allocate resources to support their growth and operational strategies.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Zoetis Inc.
Breaking Down SG&A Expenses: Eli Lilly and Company vs Amgen Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs argenx SE Trends and Insights
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Eli Lilly and Company or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Incyte Corporation
Incyte Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Incyte Corporation and Geron Corporation